The company is looking to develop further a line of cell therapy drugs used to treat solid tumors. CD Capital led the funding round with participation from Alwin Capital and Surplus Capital, according to a Sept. 2 Neukio news release.
“I am very grateful to all investors and to G&G Capital and Silkroad Law Firm for their support in this round of financing, and we will reward them with rapidly moving forward in the preclinical and clinical validation of our [research and development] platform and products,” said Richard Liqun Wang, PhD, founder, chair and CEO of Neukio.
